Literature DB >> 28212177

Neurocognitive outcomes for acute global acquired brain injury in children.

Fenella J Kirkham1.   

Abstract

PURPOSE OF REVIEW: In children, acute global brain injury from traumatic brain injury (TBI) and nontraumatic coma has a substantial cost to the child, the family, and the society. There have historically been relatively few studies looking at long-term cognition and behavioural outcomes. RECENT
FINDINGS: Long-term follow-up studies, population-based studies, and meta-analyses are now available for TBI in children as well as adults and suggest that there is a significant cognitive cost, particularly for processing speed, working memory, and intelligence quotient (IQ) in severe TBI. Poor attention is often a premorbid deficit. Children surviving a cardiac arrest typically have a reduction in IQ. The available data for meningitis suggest that IQ is within the normal range at follow-up in most but is lower than that of matched controls. For encephalitis, the main advances have been in the recognition of additional mechanisms for postinfectious causes, including autoimmune disorders and demyelination. MRI assists with diagnosis, particularly in infectious causes, and there is some evidence that it may be useful for prognosis, particularly in TBI.
SUMMARY: For the essential randomized control trials of acute treatment and rehabilitation, cognitive or MRI endpoints may become feasible as otherwise the time frame for follow-up is too long for the implementation of change.

Entities:  

Mesh:

Year:  2017        PMID: 28212177     DOI: 10.1097/WCO.0000000000000427

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  1 in total

1.  Adolescent traumatic brain injuries: Onset, mechanism and links with current academic performance and physical injuries.

Authors:  Gabriela Ilie; Michelle Trenholm; Angela Boak; Robert E Mann; Edward M Adlaf; Mark Asbridge; Hayley Hamilton; Jürgen Rehm; Robert Rutledge; Michael D Cusiman
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.